On June 25th, Gelunhui reported that Gexin Biology (2367.HK) rose by 7% to HKD 45.45, with a total market value of HKD 46.7 billion. According to CICC's report, based on the strong performance during the 618 promotion period, Gexin Biology's full-year performance is expected to exceed previous expectations, with an increase of 5%/5% in the adjusted net income forecast for 2024 and 2025 to CNY 1.92/2.28 billion. CICC maintained an 'outperform' rating and raised the target price by 7.5% to HKD 57. During the 618 promotion period (May 15th to June 20th), Komily and Kelijin's GMV increased by 60%+/100%+ respectively on online platforms, and sales of several star products ranked first in their respective sub-categories. The bank believes that there is potential for a solid foundation for Q2 performance and reiterates its bullish stance on its broad growth prospects as a leading player in recombined collagen protein, and raise its full-year performance expectations.
港股异动丨巨子生物盘中涨7% 中金料公司全年业绩有望超此前预期
HK Stock Market Changes: CanSino Biologics rose 7% during the day, and CICC expects the company's full-year performance to exceed previous expectations.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.